Tianjin Yuanye Pharmaceutical: Subsidiary passes drug GMP compliance inspection.

JinYao Pharmaceuticals announced that its subsidiary, Hubei JinYao Pharmaceuticals, recently received a "Notice of Hubei Province Drug GMP Compliance Inspection" issued by the Hubei Province Drug Administration. The inspection scope was small-volume injections/lincomycin phosphate injections, and the inspection took place from February 4 to 6, 2026, with the conclusion that it meets the requirements. The designed production capacity of this production line is 65 million units per year. In 2024 and 2025, the domestic sales of this product were 227 million and 206 million respectively, with global sales reaching 112 million and 113 million US dollars. Passing this inspection signifies an improvement in the company's production capacity, but product sales are subject to market environment uncertainties.